Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.
SYNOPSIS: Prior to initiation of hepatitis C virus treatment with direct-acting antivirals, patients should be screened for hepatitis B virus coinfection. Those who are hepatitis B virus-infected should receive ongoing monitoring for flares and reactivation of hepatitis B.
Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. Most people are asymptomatic, but for the majority of patients who become infected with hepatitis C, it becomes a long-term, chronic infection. The best way to prevent hepatitis C is by avoiding behaviors that can spread the disease, especially injection drug use, as there is no vaccine for HCV. With the forefront of direct-acting...
Occult hepatitis B infection (OBI) among HIV positive patients varies widely in different geographic regions. We undertook a study to determine the prevalence of occult hepatitis B infection among HIV infected...
(Wiley) Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.
Few patients treated with a sofosbuvir-containing regimen for hepatitis C virus infection had late recurrent viremia, and most occurrences appeared to be reinfections.
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients.
New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and deat...
Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.
New Hampshire has made communicable disease reporting changes in the state, including the reporting of hepatitis C virus. State Health Alerts
Does chronic hepatitis C infection increase diabetes risk? Liver International
The largest case review to date of hepatitis B virus (HBV) reactivation associated with direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection found no consistent pattern in terms of which patients are likely to develop this adverse event. Reuters Health Information
Vemlidy is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Europe...
Treatment options for patients with chronic HCV genotype 4 infections continue to expand. What are the currently available and investigative treatments for HCV GT4 infection? Journal of Viral Hepatitis
Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.
UK medical research charity MRC Technology has licensed an antibody to Newsummit Biopharma, a leading Chinese drug developer, in an effort to create a novel therapeutic for treating Hepatitis C virus (HCV) infection.
Hepatitis B is notoriously difficult to eradicate with currently available agents.. Now, in a new study, a novel form of "pegylated" interferon-β has reduced hepatitis B virus (HBV) infections in experimental human-derived cells and in mice more effectively than the conventional pegylated interferon-α2a, suggesting that it could lead to improved treatment for hepatitis B infection in humans. The...
Too many people infected with the hepatitis C virus (HCV) simply don’t know their disease status. As many as one in four cases of HCV infection are undiagnosed, as I pointed out in a blog earlier this year (Finding the Missing Cases), even when current federal guidelines for hepatitis C screening are closely followed. This …
French biopharmaceutical company ENYO Pharma is conducting its Phase I single and multiple ascending dose trial of EYP001 to treat Chronic Hepatitis B (CHB) Virus infection.
* Gilead - Japan's Ministry of Health, Labour and Welfare approves Gilead's Vemlidy for patients with chronic Hepatitis B virus infection Source text for Eikon: Further company coverage:
* European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection Source text for Eikon: Further company coverage:
(HealthDay)—For patients with chronic hepatitis C (CHC) treated with direct-acting antivirals (DAAs), hepatitis B virus (HBV) reactivation may occur in those with current HBV infection, according to a study published online Feb. 23 in the Journal of Gastroenterology and Hepatology.
Researchers have found that people infected with hepatitis B or C may be at significantly higher risk of developing Parkinson's disease.
The European Association for the Study of the Liver (EASL) today published their revised Clinical Practice Guidelines (CPGs) on the management of Hepatitis B virus (HBV) infection. The CPGs, which will also be presented in a session at The International Liver Congress 2017 in Amsterdam, The Netherlands, are designed to help physicians and healthcare providers optimise the management of patients wi...
Life Sciences Jobs ...